References
- Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.2149230207593
- Goodwin PJ, Shepherd FA. Economic issues in lung cancer: a review.. J Clin Oncol. 1998;16(12):3900–3912. doi:10.1200/JCO.1998.16.12.39009850036
- Urman A, Hosgood HD. Curbing the burden of lung cancer. Front Med. 2016;10(2):228–232. doi:10.1007/s11684-016-0447-x27178304
- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7–30. doi:10.3322/caac.2159031912902
- Kennedy LB, Salama AKS A. A review of cancer immunotherapy toxicity. CA Cancer J Clin. 2020;70(2):86–104. doi:10.3322/caac.2159631944278
- Herbst RS, Morgensztern D, Boshoff C. The biology and management of non-small cell lung cancer. Nature. 2018;553(7689):446–454. doi:10.1038/nature2518329364287
- Ragavan M, Das M. Systemic Therapy of Extensive Stage Small Cell Lung Cancer in the Era of Immunotherapy. Curr Treat Options Oncol. 2020;21(8):64–77. doi:10.1007/s11864-020-00762-832601742
- Lim SM, Hong MH, Kim HR. Immunotherapy for Non-small Cell Lung Cancer: current Landscape and Future Perspectives. Immune Netw. 2020;20(1):e10. doi:10.4110/in.2020.20.e1032158598
- Horn L, Mansfield AS, Szczęsna A, et al. First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer. N Engl J Med. 2018;379(23):2220–2229. doi:10.1056/NEJMoa180906430280641
- Saab S, Zalzale H, Rahal Z, et al. Insights Into Lung Cancer Immune-Based Biology, Prevention, and Treatment. Front Immunol. 2020;11:159. doi:10.3389/fimmu.2020.0015932117295
- Rizvi NA, Hellmann MD, Snyder A, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015;348(6230):124–128. doi:10.1126/science.aaa134825765070
- Topalian SL, Hodi FS, Brahmer JR, et al. Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer. N Engl J Med. 2012;366(26):2443–2454. doi:10.1056/NEJMoa120069022658127
- van Eck NJ, Waltman L. Software survey: vOSviewer, a computer program for bibliometric mapping. Scientometrics. 2010;84(2):523–538. doi:10.1007/s11192-009-0146-320585380
- Bar-Ilan J. Informetrics at the beginning of the 21st century-a review. J Informetr. 2008;2(1):1–52. doi:10.1016/j.joi.2007.11.001
- Ellegaard O, Wallin JA. The bibliometric analysis of scholarly production: how great is the impact? Scientometrics. 2015;105(3):1809–1831. doi:10.1007/s11192-015-1645-z26594073
- Dong H, Strome SE, Salomao DR, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion. Nat Med. 2002;8(8):793–800. doi:10.1038/nm73012091876
- Mok TSK, Wu Y-L, Kudaba I, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, Phase 3 trial. Lancet. 2019;393(10183):1819–1830. doi:10.1016/S0140-6736(18)32409-730955977
- Chan TA, Yarchoan M, Jaffee E, et al. Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic. Ann Oncol. 2019;30(1):44–56. doi:10.1093/annonc/mdy49530395155
- Reck M, Rodríguez–Abreu D, Robinson AG, et al. Updated Analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non–small-cell lung cancer with pd-l1 tumor proportion score of 50% or greater. J Clin Oncol. 2019;37(7):537–546. doi:10.1200/JCO.18.0014930620668
- Ott PA, Bang Y-J, Piha-Paul SA, et al. T-cell–inflamed gene-expression profile, programmed death ligand 1 expression, and tumor mutational burden predict efficacy in patients treated with pembrolizumab across 20 cancers: KEYNOTE-028. J Clin Oncol. 2019;37(4):318–327. doi:10.1200/JCO.2018.78.227630557521
- Brahmer JR, Tykodi SS, Chow LQM, et al. Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer. N Engl J Med. 2012;366(26):2455–2465. doi:10.1056/NEJMoa120069422658128
- Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer. N Engl J Med. 2015;373(17):1627–1639. doi:10.1056/NEJMoa150764326412456
- Allegranzi B, Bagheri Nejad S, Combescure C, et al. Burden of endemic health-care-associated infection in developing countries: systematic review and meta-analysis. Lancet. 2011;377(9761):228–241. doi:10.1016/S0140-6736(10)61458-421146207
- Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987–996. doi:10.1056/NEJMoa04333015758009
- Vanbutsele G, Pardon K, Van Belle S, et al. Effect of early and systematic integration of palliative care in patients with advanced cancer: a randomised controlled trial. Lancet Oncol. 2018;19(3):394–404. doi:10.1016/S1470-2045(18)30060-329402701
- Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non–small-cell lung cancer. N Engl J Med. 2015;373(2):123–135. doi:10.1056/NEJMoa150462726028407
- Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252–264. doi:10.1038/nrc323922437870
- Haratani K, Hayashi H, Chiba Y, et al. Association of immune-related adverse events with nivolumab efficacy in non–small-cell lung cancer. JAMA Oncol. 2018;4(3):374–378. doi:10.1001/jamaoncol.2017.292528975219
- Hellmann MD, Callahan MK, Awad MM, et al. Tumor mutational burden and efficacy of nivolumab monotherapy and in combination with ipilimumab in small-cell lung cancer. Cancer Cell. 2018;33(5):853–861.e4. doi:10.1016/j.ccell.2018.04.00129731394
- Hellmann MD, Paz-Ares L, Bernabe Caro R, et al. Nivolumab plus Ipilimumab in advanced non–small-cell lung cancer. N Engl J Med. 2019;381(21):2020–2031. doi:10.1056/NEJMoa191023131562796
- Rossi A. New options for combination therapy for advanced non-squamous NSCLC. Expert Rev Respir Med. 2019;13(11):1095–1107. doi:10.1080/17476348.2019.166723331512526
- Yoshimura A, Yamada T, Okuma Y, et al. Retrospective analysis of docetaxel in combination with ramucirumab for previously treated non-small cell lung cancer patients. Transl Lung Cancer Res. 2019;8(4):450–460. doi:10.21037/tlcr.2019.08.0731555518
- Vickers AD, Winfree KB, Cuyun Carter G, et al. Relative efficacy of interventions in the treatment of second-line non-small cell lung cancer: a systematic review and network meta-analysis. BMC Cancer. 2019;19(1):353. doi:10.1186/s12885-019-5569-530987609